- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00772382
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
September 5, 2014 updated by: Mitsubishi Tanabe Pharma Corporation
A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia.
The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
116
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Kamloops, British Columbia, Canada
-
-
Ontario
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
California
-
Los Angeles, California, United States
-
Orange, California, United States
-
Tarzana, California, United States
-
-
Florida
-
Orlando, Florida, United States
-
Pembroke Pines, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Gurnee, Illinois, United States
-
-
Indiana
-
Evansville, Indiana, United States
-
-
Louisiana
-
Baton Rouge, Louisiana, United States
-
New Orleans, Louisiana, United States
-
-
New York
-
Northport, New York, United States
-
-
North Carolina
-
Durham, North Carolina, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Vermont
-
Burlington, Vermont, United States
-
-
Virginia
-
Chesapeake, Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, and is >=18 years old
- Stable hemodialysis or peritoneal dialysis
- Subjects have stable phosphate control
- Subjects on stabilized phosphorus diet
- Subjects undergoing regular dialysis treatment
- Females and of child-bearing potential have a negative serum pregnancy test
- Male subjects must agree to use appropriate contraception
Exclusion Criteria:
- Current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose him/her to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study
- serum albumin level < 3.0g/L
- PTH level > 1000pg/mL
- Hemoglobin level < 8mg/dL
- A History of significant gastrointestinal motility problems
- Biliary obstruction or proven liver dysfunction
- A positive test for HIV 1 and 2 antibodies
- A history of substance or alcohol abuse within the last year
- Seizure disorders
- A history of drug or other allergy
- using cholestyramine, colestipol or colesevelam
- Schedule to receive a kidney transplant within the next 6 months
- Participation in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MCI-196
|
3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Adverse Events (AE)
Time Frame: 52 weeks
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Change in Serum Phosphorus From Baseline to Week 52
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Professor, Information at Mitsubishi Pharma America
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Actual)
August 1, 2010
Study Completion (Actual)
August 1, 2010
Study Registration Dates
First Submitted
October 10, 2008
First Submitted That Met QC Criteria
October 13, 2008
First Posted (Estimate)
October 15, 2008
Study Record Updates
Last Update Posted (Estimate)
September 15, 2014
Last Update Submitted That Met QC Criteria
September 5, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCI-196-A06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on MCI-196
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma CorporationTerminatedChronic Kidney Disease | Hyperphosphatemia | DialysisFrance, Poland, Spain, Serbia, South Africa, Czech Republic, Germany, Macedonia, The Former Yugoslav Republic of, Italy, United Kingdom
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Kidney Disease | Hyperphosphatemia | DialysisUnited States, Puerto Rico
-
Mitsubishi Tanabe Pharma CorporationCompletedDyslipidemia | Chronic Kidney Disease | Hyperphosphatemia | DialysisPoland, Ukraine, Serbia, Russian Federation, Hungary, Malaysia, Italy, Macedonia, The Former Yugoslav Republic of
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Kidney DiseaseBelarus, Bulgaria, Romania, Malaysia, Singapore, Thailand, Italy, Lithuania, Latvia, Croatia, Denmark, Israel, Indonesia
-
Northwestern UniversityNational Institutes of Health (NIH); Shirley Ryan AbilityLabRecruitingStroke | Stroke, AcuteUnited States
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Kidney Disease | HyperphosphatemiaFrance, Poland, United Kingdom, Spain, South Africa, Australia, Czech Republic, Germany, Hungary, Italy, Austria
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Kidney Disease | Hyperphosphatemia | DialysisFrance, Poland, Ukraine, United Kingdom, Spain, Serbia, South Africa, Russian Federation, Czech Republic, Germany, Hungary, Italy, Austria, Macedonia, The Former Yugoslav Republic of, Malaysia
-
University of PittsburghNational Institute of Mental Health (NIMH)Completed
-
Assistance Publique Hopitaux De MarseilleRecruiting